Corvus Pharmaceuticals (CRVS) Preferred Stock Liabilities (2015)

Corvus Pharmaceuticals (CRVS) recorded quarterly Preferred Stock Liabilities of $125.8 million in Q4 2015.

Corvus Pharmaceuticals (CRVS) Preferred Stock Liabilities (2015) Analysis & Trends

Corvus Pharmaceuticals' Preferred Stock Liabilities history runs 1 years deep, the most recent figure standing at $125.8 million for Q4 2015.

In Q4 2015, Preferred Stock Liabilities changed N/A year-over-year to $125.8 million; the TTM figure through Dec 2015 stood at $125.8 million (changed N/A YoY), while the FY2015 annual figure was $125.8 million, changed N/A from the prior year.
Preferred Stock Liabilities was $125.8 million for Q4 2015 at Corvus Pharmaceuticals.
In the past five years, Preferred Stock Liabilities ranged from a high of $125.8 million in Q4 2015 to a low of $125.8 million in Q4 2015.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Preferred Stock Liabilities (Qtr)
1	Alterity Therapeutics	762,369.55 Bn	762,369.51 Bn	-	-
2	Belite Bio	55,096.00 Bn	55,096.00 Bn	-	-
3	Quantum Biopharma	17,755.80 Bn	17,755.79 Bn	-	-
4	Legend Biotech	3,486.00 Bn	3,485.71 Bn	242.10 Mn	-
5	Akari Therapeutics	1,737.42 Bn	1,737.41 Bn	-	-
6	Evaxion A	1,551.28 Bn	1,551.26 Bn	-	-
7	Psyence Biomedical	227.32 Bn	227.31 Bn	-	-
8	Vertex Pharmaceuticals	110.84 Bn	103.59 Bn	2.59 Bn	-
9	Abivax	91.71 Bn	91.71 Bn	-	-
10	Corvus Pharmaceuticals	1.00 Bn	766.75 Mn	-	-

Download Data

Date	Value
Dec 31, 2015	125.78 Mn